211 related articles for article (PubMed ID: 19696677)
21. Update in Cystic Fibrosis 2014.
Ong T; Ramsey BW
Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
[No Abstract] [Full Text] [Related]
22. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Jones AM; Barry PJ
Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
[No Abstract] [Full Text] [Related]
23. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
24. [Causal therapy is available].
Meißner T
MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
[No Abstract] [Full Text] [Related]
25. Remarkable progress toward new treatments for cystic fibrosis.
Eldredge LC; Ramsey BW
Lancet Respir Med; 2014 Dec; 2(12):962-4. PubMed ID: 25466347
[No Abstract] [Full Text] [Related]
26. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
27. Cystic fibrosis drug is not cost effective, says NICE.
Gulland A
BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
[No Abstract] [Full Text] [Related]
28. Radical new treatments for cystic fibrosis.
Arch Dis Child; 2015 Aug; 100(8):727. PubMed ID: 26078470
[No Abstract] [Full Text] [Related]
29. Cystic fibrosis drug Vertex's latest triumph.
Ledford H
Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
[No Abstract] [Full Text] [Related]
30. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Mitchell RM; Jones AM; Barry PJ
Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
[TBL] [Abstract][Full Text] [Related]
31. Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
VanDevanter DR; Mayer-Hamblett N
Curr Opin Pulm Med; 2017 Nov; 23(6):530-535. PubMed ID: 28708817
[TBL] [Abstract][Full Text] [Related]
32. Lung clearance index response in patients with CF with class III CFTR mutations.
Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
[No Abstract] [Full Text] [Related]
33. Precision Medicine: At What Price?
Ferkol T; Quinton P
Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
[No Abstract] [Full Text] [Related]
34. The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.
Eckford PDW; McCormack J; Munsie L; He G; Stanojevic S; Pereira SL; Ho K; Avolio J; Bartlett C; Yang JY; Wong AP; Wellhauser L; Huan LJ; Jiang JX; Ouyang H; Du K; Klingel M; Kyriakopoulou L; Gonska T; Moraes TJ; Strug LJ; Rossant J; Ratjen F; Bear CE
J Cyst Fibros; 2019 Jan; 18(1):35-43. PubMed ID: 29685812
[TBL] [Abstract][Full Text] [Related]
35. Excitement mounts for first disease-modifying cystic fibrosis drugs.
Opar A
Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
[No Abstract] [Full Text] [Related]
36. Cystic fibrosis in the era of genomic medicine.
Milla CE
Curr Opin Pediatr; 2013 Jun; 25(3):323-8. PubMed ID: 23652683
[TBL] [Abstract][Full Text] [Related]
37. Breathing easier with combinations.
Azvolinsky A
Nat Biotechnol; 2015 Nov; 33(11):1128-30. PubMed ID: 26544137
[No Abstract] [Full Text] [Related]
38. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
Hayes D; Long FR; McCoy KS; Sheikh SI
Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
[No Abstract] [Full Text] [Related]
39. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Tümmler B
Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
[No Abstract] [Full Text] [Related]
40. Emerging therapies in cystic fibrosis.
Anderson P
Ther Adv Respir Dis; 2010 Jun; 4(3):177-85. PubMed ID: 20530065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]